Cambrex (NYSE:CBM) was upgraded by Zacks Investment Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Monday.

According to Zacks, “Cambrex Corporation is an innovative life sciences company with a refreshingly human approach. Driven by passion, their pharmaceutical products, expertise and technologies accelerate customers’ small molecule therapeutics into markets across the world. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. Cambrex has transformed from a fine chemical manufacturer to a business with a singular focus on small molecule therapeutics. “

Separately, Craig Hallum reissued a “buy” rating and issued a $60.00 price target (down previously from $70.00) on shares of Cambrex in a report on Tuesday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $62.33.

Shares of Cambrex (NYSE:CBM) traded down $0.15 on Monday, reaching $51.65. The company had a trading volume of 151,200 shares, compared to its average volume of 293,567. The stock has a market capitalization of $1,692.96, a P/E ratio of 17.22, a P/E/G ratio of 1.25 and a beta of 2.27. Cambrex has a 1 year low of $42.55 and a 1 year high of $62.95.

Cambrex (NYSE:CBM) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.08. The firm had revenue of $112.60 million during the quarter, compared to the consensus estimate of $108.44 million. Cambrex had a return on equity of 23.42% and a net margin of 18.79%. Cambrex’s revenue for the quarter was up 13.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.47 earnings per share. equities research analysts expect that Cambrex will post 2.97 EPS for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of CBM. Schwab Charles Investment Management Inc. boosted its holdings in Cambrex by 3.1% in the second quarter. Schwab Charles Investment Management Inc. now owns 150,109 shares of the biotechnology company’s stock valued at $8,970,000 after purchasing an additional 4,582 shares during the last quarter. Swiss National Bank boosted its holdings in Cambrex by 2.8% in the second quarter. Swiss National Bank now owns 54,400 shares of the biotechnology company’s stock valued at $3,250,000 after purchasing an additional 1,500 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its stake in Cambrex by 29.9% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 8,781 shares of the biotechnology company’s stock valued at $525,000 after buying an additional 2,020 shares in the last quarter. Riverhead Capital Management LLC raised its stake in Cambrex by 90.3% during the second quarter. Riverhead Capital Management LLC now owns 2,664 shares of the biotechnology company’s stock valued at $159,000 after buying an additional 1,264 shares in the last quarter. Finally, Teachers Advisors LLC raised its stake in Cambrex by 3.4% during the second quarter. Teachers Advisors LLC now owns 353,138 shares of the biotechnology company’s stock valued at $21,100,000 after buying an additional 11,592 shares in the last quarter.

TRADEMARK VIOLATION NOTICE: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2018/01/15/cambrex-cbm-upgraded-to-hold-at-zacks-investment-research.html.

About Cambrex

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.

Get a free copy of the Zacks research report on Cambrex (CBM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.